Clinical Trial Update: Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack. [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluates dapagliflozin for cardiometabolic outcomes in patients after an acute myocardial infarction. The study includes participants with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Myocardial Infarction

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Acute Myocardial Infarction, Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2025-03-07